Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NBTX 
Nanobiotix (NBTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: NBTX (3-star) is a SELL. SELL since 4 days. Simulated Profits (471.65%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.13
1 Year Target Price $15.13
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 380.36% | Avg. Invested days 46 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 992.79M USD | Price to earnings Ratio - | 1Y Target Price 15.13 |
Price to earnings Ratio - | 1Y Target Price 15.13 | ||
Volume (30-day avg) 4 | Beta 1.64 | 52 Weeks Range 2.76 - 30.35 | Updated Date 10/27/2025 |
52 Weeks Range 2.76 - 30.35 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 3.06% |
Management Effectiveness
Return on Assets (TTM) -41.64% | Return on Equity (TTM) -198.69% |
Valuation
Trailing PE - | Forward PE 333.33 | Enterprise Value 982344927 | Price to Sales(TTM) 97.73 |
Enterprise Value 982344927 | Price to Sales(TTM) 97.73 | ||
Enterprise Value to Revenue 117 | Enterprise Value to EBITDA -2.45 | Shares Outstanding 48215353 | Shares Floating 30854421 |
Shares Outstanding 48215353 | Shares Floating 30854421 | ||
Percent Insiders - | Percent Institutions 11.71 |
Upturn AI SWOT
Nanobiotix
Company Overview
History and Background
Nanobiotix was founded in 2003. They are a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for cancer patients. Significant milestones include the development of their lead product, NBTXR3, and progression through clinical trials.
Core Business Areas
- Oncology: Focuses on developing and commercializing NanoXray-based products for cancer treatment. NBTXR3 is the lead product.
Leadership and Structure
The company is led by Laurent Levy (Chairman and CEO). The structure includes research & development, clinical operations, commercialization, and administrative functions.
Top Products and Market Share
Key Offerings
- NBTXR3 (Hensify): NBTXR3 is a nanoparticle formulation designed to enhance radiotherapy efficacy in various cancers. Currently approved for soft tissue sarcoma in Europe. Revenue data is emerging as the commercialization strategy ramps up. Competitors include conventional radiation therapy approaches and other radiosensitizers in development.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by increasing cancer incidence and advancements in treatment. The industry is highly competitive and includes pharmaceuticals, biotechnology companies, and medical device manufacturers.
Positioning
Nanobiotix aims to improve cancer treatment outcomes by enhancing the effects of radiotherapy. NBTXR3 aims to provide a physics-based approach to improve outcomes in cancer treatments.
Total Addressable Market (TAM)
The TAM for NBTXR3 includes the radiotherapy market across multiple cancer indications, potentially reaching billions of dollars. Nanobiotix aims to capture a significant share by demonstrating clinical efficacy and expanding approved indications.
Upturn SWOT Analysis
Strengths
- Proprietary NanoXray technology
- Promising clinical trial results for NBTXR3
- Experienced management team
- European market approval for soft tissue sarcoma
Weaknesses
- Limited commercialization experience
- Dependence on NBTXR3
- Cash burn rate
- Requirement for regulatory approvals in other markets (e.g., US)
Opportunities
- Expanding NBTXR3 indications
- Partnerships with pharmaceutical companies
- US FDA approval
- Development of new NanoXray products
Threats
- Competition from existing cancer treatments
- Clinical trial failures
- Regulatory hurdles
- Financial market volatility
Competitors and Market Share
Key Competitors
- Varian Medical Systems (VAR)
- Elekta AB (EKTAY)
- IBA (IBABF)
Competitive Landscape
Nanobiotix competes with established radiation therapy equipment manufacturers and companies developing novel cancer treatments. The competitive advantage lies in their unique NanoXray technology. Lack of financial resources is a main disadvantage for NBTX
Growth Trajectory and Initiatives
Historical Growth: Growth driven by clinical trial progress and regulatory approvals.
Future Projections: Future growth is dependent on expanding NBTXR3 indications and commercialization efforts.
Recent Initiatives: Focus on ongoing clinical trials (e.g., head and neck cancer) and preparing for commercial launch in additional markets.
Summary
Nanobiotix is a biotechnology company with a promising lead product in NBTXR3. While they have achieved regulatory approval in Europe, they face challenges in expanding commercialization and securing funding. Successful clinical trials and strategic partnerships are crucial for their future success. Investors should monitor regulatory approvals, market uptake, and financial stability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Clinical trial data
- Analyst reports (where available and applicable)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may not be completely accurate. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nanobiotix
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-11 | Co-Founder, President of the Executive Board & CEO Mr. Laurent Levy Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | Website https://www.nanobiotix.com |
Full time employees 103 | Website https://www.nanobiotix.com | ||
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.